

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT

INCREASE IN SHAREHOLDING BY CEO AND EXECUTIVE DIRECTOR DR. JIANXIN YANG BY 976,000 SHARES, WITH ACCUMULATED PURCHASE TOTALING 12,477,000 SHARES

This announcement is made by CStone Pharmaceuticals (the “Company”, together with its subsidiaries, collectively referred to as the “Group” or “CStone”) on a voluntary basis to inform its shareholders and potential investors in relation to the increase in shareholding in the Company (the “Shares”) by Dr. Jianxin Yang (“Dr. Yang”), the chief executive officer (the “CEO”), president of research and development and an executive director of the Company.

The Company was informed by Dr. Yang that he has purchased an aggregate of 976,000 Shares in the open market using personal funds from November 2025 to January 2026 (the “Share Purchases”), of which 428,500 shares were acquired solely on January 22 and January 23, 2026.

This recent purchase continues a pattern of strong commitment from Dr. Yang. Since assuming the role as CEO in August 2022, Dr. Yang has cumulatively purchased a total of 12,477,000 Shares in the open market. Dr. Yang’s total shareholding interest in the Company represents approximately 4.87% of the total issued share capital of the Company as at the date of this announcement.

Dr. Yang expressed his strong confidence in the Company’s long-term investment value and core competitive advantages. The increase in his shareholding in the Company represents his belief in the Company’s ability to maintain steady operations and to achieve high-quality growth in the future. Dr. Yang does not rule out the possibility of further increasing his shareholding in the Company as and when appropriate.

The board of directors of the Company (the “Board”) is of the view that the increase in shareholding of the Company by Dr. Yang signifies his long-term commitment to, and confidence towards, the future business prospects of the Company.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 20 new drug applications covering 9 indications. The Company's pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, January 27, 2026

As at the date of this announcement, the Board comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III and Mr. Edward Hu as non-executive directors, and Mr. Kenneth Howard Jarrett, Ms. Fang Xie and Ms. Catherine Yen as independent non-executive directors.